Global Drug Delivery Devices Market by Route of Administration (Injectable, Oral, Transdermal) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028

Summary of the Report

Global drug delivery devices market was worth USD 215.4 billion in 2019. It is expected to grow at a CAGR (6.15%) over the forecast period. The overall market growth is expected to be driven by the adoption of more advanced technology for delivering drugs on target sites. These drug delivery devices can reduce side effects and optimize drug presence at the target location. This reduces side effects and dose. This also helps to reduce the product's overall price by reducing its active pharmaceutical ingredient.

The R&D sector is expected to grow due to the increasing demand for novel drug delivery systems. In order to develop innovative technology for different applications, major market players continue to form strategic alliances. AstraZeneca partnered with Aptamer Group in January 2019 to explore its technology for developing a new drug delivery device for the kidney. Patients are also more likely to access these devices through home-care settings, which is increasing their acceptance of drug delivery devices.

Due to increasing demand, many companies are creating patient-friendly drug delivery systems. Other market players are also buying these companies in order to increase their portfolio. Aptar Pharma purchased Noble International, a company that developed training drug delivery devices. Noble International has developed advanced drug delivery devices that are patient-centric, such as prefilled Syringes and Auto-Injectors. This acquisition will allow patients to administer medication properly using advanced drug delivery devices.

Currently, research is ongoing to improve drug delivery technology. This will make it easier, more accessible, and more accurate for patients. Players are constantly researching new technologies and developing advanced drug delivery systems in line with this. Phillips-Medisize (now a subsidiary of Molex Company) announced in October 2019 that they would launch a combination device and an electronic-enabled wearable drug delivery system. The product currently combines disposable technology for subcutaneous drug delivery that is two-day-per-use and disposable. It is in the third phase of development. The company has submitted the New Drug Application to the Food and Drug Administration with supporting data. This product will be available for sale in the second half 2020. The advancements in polymer science are also helping to improve drug delivery devices. These unique polymers will improve the accuracy of drug delivery. The development of drug delivery devices that are technologically advanced is expected to drive market growth over the forecast period.

These drug delivery devices have many advantages, but there are certain limitations that could hinder market growth. This drug delivery device's main problem is its inability to deliver poorly soluble drugs. Market growth will also be affected by other bioavailability issues associated with poorly soluble drugs. These drug delivery devices can release uncontrolled drugs at the site of infection, which could later cause side effects like allergies and infections.

Route of Administration Insights

The market can be divided by the method of administration. Subcutaneous, intradermal and intravenous are other routes of administration. In 2019, the oral route was the most popular and will continue to grow significantly over the forecast period.

Oral drug delivery systems include a variety of dosage forms, including capsules, syrups and solutions as well as tablets and suspensions. This category also includes drugs delivery products like tablets and films. In terms of safety, affordability, drug stability, and ease of use, the oral route is preferred. Inhalation is preferred for patients with pulmonary conditions like asthma or chronic obstructive pulmonary disease (COPD). This segment is expected to grow due to factors such as the increasing prevalence of respiratory conditions and technological advances in devices for inhalation delivery, such as nebulizers or inhalers.

The fastest growing route of administration for injectable drugs is expected to be the one that expands the most during the forecast period. Injectable drug delivery systems have seen significant improvements in recent years, including the introduction of prefilled Syringes and Pen Injectors. This has increased the market's demand. The market is also being driven by the development of polymers for syringes, which are inert towards most chemicals.

Application Insights

The market can be divided by application into oncology and infectious diseases, respiratory disease, diabetes, heart disease, diabetes, heart disease, autoimmune diseases, neurology, etc. Other segments include endocrine disorders, ophthalmic diseases, and others. The largest market share was held by diabetes drug delivery devices in 2019. The increasing prevalence of diabetes is the main reason for this. According to the American Diabetes Association (ADA), 34.2 Million Americans were affected by diabetes in 2018. Of these, 26.8M were diagnosed with diabetes and 7.3M were not. An increasing number of diabetic cases will likely lead to the adoption of drug delivery systems in the field.

Oncology accounted for a large share of the market. It is expected to continue growing at a moderate pace over the forecast period due to the rising incidence of cancer around the world. Around 1.7 million cases of cancer were diagnosed in the U.S. in 2018. Liposomal and albumin-nanoparticle drug delivery systems are the most popular in oncology.

The segment of Central Nervous System disorders (CNS), is expected to grow at the fastest rate over the forecast period. The segment's growth is expected to be boosted by the increasing incidence of neurological disorders like Parkinson's disease, Alzheimer's disease and Hunter's syndrome. New drug delivery devices for CNS are being created to improve the treatment of neurological disorders. They are based on rational drug design, receptor-ligand interaction, and use drug delivery sites that have been proven effective.

Vehicle Insights

The market for drug delivery devices is divided by vehicle type into micelle, dendrimer and nanoparticle. The most widely used drug delivery vehicle is the liposome. This vehicle's advantages are expected to help the segment grow. The liposome drug delivery device is non-immunogenic and non-hemolytic. It also has no toxic effects. It is also biodegradable, biocompatible, and can be used to avoid clearance mechanisms like renal clearance, reticuloendothelial systems, chemical or enzymatic activation.

The popularity of hydrogels in 2019 was due to their porosity and compatibility within an aqueous environment. This makes them an attractive drug delivery vehicle. These hydrogels are also versatile and can be made into a variety of forms, including microparticles or slabs, nanoparticles or films. This will increase its acceptance for various purposes. Hydrogels' physical properties also make it possible to sustain drug release at the site. This vehicle will allow for controlled drug delivery, which is expected to drive the segment's growth.

The fastest growing segment during the forecast period is the nanoparticle drug delivery vehicle. This segment is expected to grow due to increased research and investigation into nanoparticles as drug delivery vehicles. For many applications, nanoparticles can be used as a drug delivery vehicle. For the preparation of polymeric nanoparticles, both hydrophilic and hydrophobic blocks are used. This allows them to contain both hydrophobic as well as hydrophilic drugs. Its structure is also useful in binding macromolecules like proteins, nucleic acid, and antibodies. The segment's growth is expected to be boosted by the increasing use and development of nanoparticle drug delivery devices.

End-use Insights

The market can be divided by end-use into hospitals, diagnostic centres, /ambulatory surgery centers/clinics and home care settings. Other segments include universities, research centers, and institutes. The largest share of hospitals in 2019 was due to rising cases of neurological disorders, diabetes, cancer and other diseases. Different drugs are required for different conditions. Hospital-acquired infections are expected to reduce the use of hospital drug delivery devices, which could impact segment growth over the forecast period.

In 2019, a large share of the market was held by diagnostic centers. Numerous diagnostic centers are working to develop and implement novel drug delivery systems that deliver drugs precisely. The Center for Drug Delivery and Nanomedicine is focused on gathering existing scientific and technical knowledge in biomedical science research and material for developing a nanomedicine program and interdisciplinarity drug delivery. The center's main purpose is to study the safety and efficacy of different drugs and to create innovative delivery methods.

Home care settings will experience the fastest rate of growth during the forecast period. The growth of this sector is mainly due to growing hospital-acquired infection rates, high-cost and longer waiting times in hospitals. This is leading to a rise in self-administration, which is resulting in more treatments at-home than in hospitals or other diagnostic centers.

Regional Insights

North America dominated the market, largely due the presence of large players in the region as well as the growing use of drug delivery devices. Market growth is expected to be boosted by increased awareness of the benefits of drug delivery devices in the region. Market growth will also be supported by the U.S.'s increasing product approval. Aptar Pharma was approved by the FDA in March 2019 for its nasal drug delivery device.

The Europe region accounted for a large share of the global market in 2019, and it is expected to continue growing at a moderate pace. The region's major market players have huge opportunities due to its developed economies and their favorable regulatory processes. Due to the high level of economic growth, Asia Pacific will experience the fastest rate of growth over the forecast period. A large patient population in countries such as India, China, and Japan is driving the adoption of drug delivery systems by different end-users. Different types of drug delivery devices can be used in Japan to deliver specific drugs. YpsoMate, an autoinjector from YpsoMate, entered the Japanese market in December 2019 to deliver Teribone drug accurately. Market growth is expected to be boosted by the increasing adoption of drug delivery devices in this region.

Market Share in Drug Delivery Devices

Pfizer, Inc., Johnson & Johnson Services, Inc., F. Hoffmann-La Roche, Ltd., Novartis AG, BD; Bayer AG, uniQure N.V., and Sibiono GeneTech Co. Ltd. are the major players in this market. There are many local and global players in this market.

To increase their product portfolio, market players are creating strategic alliances through collaborations and partnerships. In September 2016, DelSiTech signed a technology license agreement with Bayer to develop innovative delivery technology for the field of ophthalmology. SMC Ltd. also announced in December 2016 that it had acquired Oval Medical Technologies Ltd. to expand its product portfolio and add the advanced autoinjectors of the latter. Consequently, the market is expected to grow by forming alliances in the development of drug delivery device.

Scope of the Report

The Report Covers Certain Segments

This report provides a forecast of revenue and volume growth at the global, regional and country level. It also analyzes the most recent industry trends for each sub-segment from 2016 to 2027. Grand View Research segmented the global market for drug delivery devices based on route of administration, vehicle, end use, region, and application.

• Route of Administration Outlook (Volume and Units; Revenue USD Billion, 2016-2027)

  • Oral

  • Inhalation

  • Transdermal

  • Injectable

  • Ocular

  • Nasal

  • Topical

  • Other

• Application Outlook (Revenue, USD Billion, 2016 - 2027)

  • Oncology

  • Infectious Diseases

  • Respiratory Diseases

  • Diabetes

  • Cardiovascular Diseases

  • Autoimmune Diseases

  • Central Nervous System Disorders

  • Other

• End-use Outlook (Revenue, USD Billion, 2016 - 2027)

  • Hospitals

  • Diagnostic Centers

  • Ambulatory Surgery Centers/Clinics

  • Home Care Options

  • Other

• Vehicle Outlook (Volume and Units; Revenue USD Billion, 2016-2027)

  • Hydrogel

    • Oncology

    • Infectious Diseases

    • Respiratory Diseases

    • Diabetes

    • Cardiovascular Diseases

    • Autoimmune Diseases

    • Central Nervous System Disorders

    • Other

  • Micelle

    • Oncology

    • Infectious Diseases

    • Respiratory Diseases

    • Diabetes

    • Cardiovascular Diseases

    • Autoimmune Diseases

    • Central Nervous System Disorders

    • Other

  • Dendrimer

    • Oncology

    • Infectious Diseases

    • Respiratory Diseases

    • Diabetes

    • Cardiovascular Diseases

    • Autoimmune Diseases

    • Central Nervous System Disorders

    • Other

  • Nanoparticle

    • Oncology

    • Infectious Diseases

    • Respiratory Diseases

    • Diabetes

    • Cardiovascular Diseases

    • Autoimmune Diseases

    • Central Nervous System Disorders

    • Other

  • Liposome

    • Oncology

    • Infectious Diseases

    • Respiratory Diseases

    • Diabetes

    • Cardiovascular Diseases

    • Autoimmune Diseases

    • Central Nervous System Disorders

    • Other

  • Scaffold

    • Oncology

    • Infectious Diseases

    • Respiratory Diseases

    • Diabetes

    • Cardiovascular Diseases

    • Autoimmune Diseases

    • Central Nervous System Disorders

    • Other

  • Mesoporous Material

    • Oncology

    • Infectious Diseases

    • Respiratory Diseases

    • Diabetes

    • Cardiovascular Diseases

    • Autoimmune Diseases

    • Central Nervous System Disorders

    • Other

  • Niosomes

    • Oncology

    • Infectious Diseases

    • Respiratory Diseases

    • Diabetes

    • Cardiovascular Diseases

    • Autoimmune Diseases

    • Central Nervous System Disorders

    • Other

• Regional Outlook (Volume and Units; Revenue USD Billion, 2016-2027)

  • North America

    • The U.S.

    • Canada

  • Europe

    • Germany

    • The U.K.

    • France

    • Italy

    • Spain

    • Russia

    • The Netherlands

    • Switzerland

    • Turkey

    • Poland

  • Asia Pacific

    • China

    • Japan

    • India

    • Thailand

    • South Korea

    • Indonesia

    • Taiwan

    • Hong Kong

    • Philippines

    • Malaysia

  • Latin America

    • Brazil

    • Mexico

    • Argentina

    • Colombia

    • Chile

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

    • Qatar

These are the most frequently asked questions about this report

b. Global drug delivery device market was valued at USD 215.4 billion in 2019, and is forecast to grow to USD 227.7 trillion in 2020.

b. Global drug delivery device market is expected grow at 6.2% compound annual growth rate between 2020 and 2027, to reach USD 345.8 trillion by 2027.

b. With a 32.45% share in 2019, North America dominated drug delivery devices markets. This is due to the strong presence of market leaders in the region as well as the growing trend towards targeted drug deliveries.

b. Pfizer, Inc, Johnson & Johnson Services, Inc., F. Hoffmann-La Roche, Ltd., Novartis AG, BD, Bayer AG, uniQureN.V., Sibiono GeneTech Co. Ltd., Shanghai Sunway Biotech Co., Ltd., and Human Stem Cells Institute are some of the key players in the market for drug delivery devices.

b. Market growth is being driven by the growing prevalence of chronic diseases, the importance of developing a patient-complaint drug delivery system and the increased R&D spending by pharma companies in drug delivery devices.

Up Market Research published a new report titled “Drug Delivery Devices Market research report which is segmented by Route of Administration (Injectable, Oral, Transdermal), By Players/Companies Shanghai Sunway Biotech Co, Johnson & Johnson Services, BD, Novartis AG, Inc, F Hoffmann-La Roche, Ltd, Inc, Sibiono GeneTech Co Ltd, Human Stem Cells Institute, Bayer AG, uniQure NV, Ltd, Pfizer”. As per the study the market is expected to grow at a CAGR of XX% in the forecast period.

Report Scope

The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.

Global Drug Delivery Devices Market Report Segments:

The market is segmented by Route of Administration (Injectable, Oral, Transdermal).

Drug Delivery Devices Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.

Key Benefits for Industry Participants & Stakeholders:

• Industry drivers, restraints, and opportunities covered in the study
• Neutral perspective on the market performance
• Recent industry trends and developments
• Competitive landscape & strategies of key players
• Potential & niche segments and regions exhibiting promising growth covered
• Historical, current, and projected market size, in terms of value
• In-depth analysis of the Drug Delivery Devices Market

Overview of the regional outlook of the Drug Delivery Devices Market:

Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.

Highlights of The Drug Delivery Devices Market Report:

1. The market structure and projections for the coming years.
2. Drivers, restraints, opportunities, and current trends of Drug Delivery Devices Market.
3. Historical data and forecast.
4. Estimations for the forecast period 2028.
5. Developments and trends in the market.

                1. Injectable

                2. Oral

                3. Transdermal

7. Market scenario by region, sub-region, and country.
8. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
9. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
10. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Drug Delivery Devices Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.

How you may use our products:

• Correctly Positioning New Products
• Market Entry Strategies
• Business Expansion Strategies
• Consumer Insights
• Understanding Competition Scenario
• Product & Brand Management
• Channel & Customer Management
• Identifying Appropriate Advertising Appeals

Reasons to Purchase the Drug Delivery Devices Market Report:

• The report includes a plethora of information such as market dynamics scenario and opportunities during the forecast period
• Segments and sub-segments include quantitative, qualitative, value (USD Million,) and volume (Units Million) data.
• Regional, sub-regional, and country level data includes the demand and supply forces along with their influence on the market.
• The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
• Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.